Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
>,10708180,gastric residual volumes,"Ten adult, critically ill, mechanically ventilated patients not tolerating a fiber-containing EN product defined as a single aspirated gastric residual volume >150 mL or two aspirated gastric residual volumes >120 mL during a 12-hr period.","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),,120,15818,DB00604,Cisapride
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,6.3,15819,DB00604,Cisapride
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,10.9,15820,DB00604,Cisapride
,10708180,mean residence time of absorption,"Metoclopramide and cisapride had a significantly shorter mean residence time of absorption than erythromycin (6.3+/-4.5 [SEM] mins and 10.9+/-5.8 vs. 30.1+/-4.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,30.1,15821,DB00604,Cisapride
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,9.7,15822,DB00604,Cisapride
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,60.7,15823,DB00604,Cisapride
,10708180,time to peak concentration,"Metoclopramide (9.7+/-15.3 mins) had a significantly shorter time to peak concentration compared with erythromycin and placebo (60.7+/-8.1 and 50.9+/-13.5 mins, respectively [p<.05]).","Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,50.9,15824,DB00604,Cisapride
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,5.7,15825,DB00604,Cisapride
,10708180,time to onset of absorption,The time to onset of absorption was significantly shorter for metoclopramide vs. cisapride (5.7+/-4.5 vs. 22.9+/-5.7 mins [p<.05]).,"Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10708180/),min,22.9,15826,DB00604,Cisapride
,10579471,time of the peak concentration,The time of the peak concentration of cisapride was prolonged from 1.5 to 2.5 hours (P < .05) and the elimination half-life from 6.8 to 8.4 hours (P < .05) by grapefruit juice.,Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579471/),h,1.5 to 2.5,16279,DB00604,Cisapride
,10579471,elimination half-life,The time of the peak concentration of cisapride was prolonged from 1.5 to 2.5 hours (P < .05) and the elimination half-life from 6.8 to 8.4 hours (P < .05) by grapefruit juice.,Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579471/),h,6.8 to 8.4,16280,DB00604,Cisapride
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1070,25049,DB00604,Cisapride
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1051,25050,DB00604,Cisapride
,1618258,AUC,"Mean plasma paracetamol AUC at 60 min were 1070, 1051 and 1031 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,1031,25051,DB00604,Cisapride
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,31.5,25052,DB00604,Cisapride
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,29.3,25053,DB00604,Cisapride
,1618258,maximum paracetamol concentrations,"ml-1 and maximum paracetamol concentrations were 31.5, 29.3 and 27.4 micrograms.",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),μg,27.4,25054,DB00604,Cisapride
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25055,DB00604,Cisapride
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25056,DB00604,Cisapride
,1618258,time to maximum paracetamol concentration,"There was no difference also in time to maximum paracetamol concentration [median (range) 30 (15-120), 30 (15-90) and 30 (15-60) min, respectively].",No effect of cisapride on paracetamol absorption after oral simultaneous administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618258/),min,30,25057,DB00604,Cisapride
,11996495,flow-rate,"HPLC separation was achieved on a C18 column with the mobile phase of acetonitrile-50 mM sodium dihydrogen phosphate (60:40, v/v) at a flow-rate of 1 ml/min.",Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),[ml] / [min],1,29813,DB00604,Cisapride
,11996495,retention time,The retention time was about 5.3 min for delavirdine and 6.5 min for cisapride.,Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),min,5.3,29814,DB00604,Cisapride
,11996495,retention time,The retention time was about 5.3 min for delavirdine and 6.5 min for cisapride.,Determination of delavirdine in very small volumes of plasma by high-performance liquid chromatography with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996495/),min,6.5,29815,DB00604,Cisapride
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,5.6,36615,DB00604,Cisapride
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,10.3,36616,DB00604,Cisapride
,24363733,retention time,"The retention time of internal standard (cisapride), clomipramine, and desmethyl clomipramine were 5.6 ± 0.2, 10.3 ± 0.3, and 9.5 ± 0.3 min, respectively.",A Simple Sample Preparation with HPLC-UV Method for Estimation of Clomipramine from Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363733/),min,9.5,36617,DB00604,Cisapride
,9401693,peak plasma concentration,"After i.v. administration, peak plasma concentration was 221.4 ng/ml and harmonic mean half-life was 1.9 hours.",Pharmacokinetics of cisapride in horses after intravenous and rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401693/),[ng] / [ml],221.4,36977,DB00604,Cisapride
,9401693,half-life,"After i.v. administration, peak plasma concentration was 221.4 ng/ml and harmonic mean half-life was 1.9 hours.",Pharmacokinetics of cisapride in horses after intravenous and rectal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401693/),h,1.9,36978,DB00604,Cisapride
,9401693,systemic availability,Cisapride was detected in plasma from only 3 of 5 horses for which mean systemic availability was 1.23%.,Pharmacokinetics of cisapride in horses after intravenous and rectal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401693/),%,1.23,36979,DB00604,Cisapride
,9401693,maximal plasma concentration,Mean maximal plasma concentration after rectal administration of cisapride was 13.5 ng/ml.,Pharmacokinetics of cisapride in horses after intravenous and rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9401693/),[ng] / [ml],13.5,36980,DB00604,Cisapride
,14581078,recoveries,"The recoveries of tiropramide ranged from 50.2 to 53.1%, with that of cisapride (internal standard) being 60.9+/-5.3%.",Determination of tiropramide in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581078/),%,50.2 to 53.1,39738,DB00604,Cisapride
,14581078,recoveries,"The recoveries of tiropramide ranged from 50.2 to 53.1%, with that of cisapride (internal standard) being 60.9+/-5.3%.",Determination of tiropramide in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14581078/),%,60.9,39739,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1.4,41849,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,4.0,41850,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,2.5,41851,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1300,41852,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,1800,41853,DB00604,Cisapride
,17689270,CE10ms,"In the conscious telemetered, conscious paced, and anesthetized dog models, the mean CE10ms values were 1.4, 4.0, and 2.5 nM for dofetilide and 1300, 1800, and 12,200 nM for moxifloxacin.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,"12,200",41854,DB00604,Cisapride
,17689270,CE10ms,"For cisapride, the CE10ms values were 8.0 and 4.4 nM in the conscious telemetered and conscious paced dog models.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,8.0,41855,DB00604,Cisapride
,17689270,CE10ms,"For cisapride, the CE10ms values were 8.0 and 4.4 nM in the conscious telemetered and conscious paced dog models.",Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17689270/),nM,4.4,41856,DB00604,Cisapride
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),[ng] / [ml],12.5,41954,DB00604,Cisapride
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),%,20,41955,DB00604,Cisapride
,10993514,C.V.s,"Intra- and inter-day C.V.s did not exceed 15% for all concentrations except at 12.5 ng/ml for EII (+)-cisapride, which was approximately 20 and 19%, respectively.","Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10993514/),%,19,41956,DB00604,Cisapride
>,9620098,trough:peak ratios,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),%,80,47827,DB00604,Cisapride
,9620098,elimination half-life,"Favorable hemodynamic and clinical profiles are reported, including high trough:peak ratios (> 80%), high oral bioavailability, and long elimination half-life (17-25 hrs) permitting once/day dosing.","Mibefradil, a pharmacologically distinct calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9620098/),h,17-25,47828,DB00604,Cisapride
,21605652,Time to reach peak concentration,"Time to reach peak concentration of meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[mg] / [l],0.371,50789,DB00604,Cisapride
,21605652,Time to reach peak concentration,"Time to reach peak concentration of meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[mg] / [l],0.199,50790,DB00604,Cisapride
,21605652,Time to reach peak concentration,"Time to reach peak concentration of meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),min,23.57,50791,DB00604,Cisapride
,21605652,Time to reach peak concentration,"Time to reach peak concentration of meranzin hydrate (0.371 mg/L) and ferulic acid (0.199 mg/L) was 23.57 min and 27.50 min, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),min,27.50,50792,DB00604,Cisapride
,21605652,elimination half-life,"The elimination half-life and area under the concentration-time curve from t=0 to the last time of meranzin hydrate and ferulic acid were 139.53 min and 31.445 μg min/mL and 131.27 min and 14.835 μg min/mL, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),min,139.53,50793,DB00604,Cisapride
,21605652,elimination half-life,"The elimination half-life and area under the concentration-time curve from t=0 to the last time of meranzin hydrate and ferulic acid were 139.53 min and 31.445 μg min/mL and 131.27 min and 14.835 μg min/mL, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),min,131.27,50794,DB00604,Cisapride
,21605652,area under the concentration-time curve from t=0 to the last time,"The elimination half-life and area under the concentration-time curve from t=0 to the last time of meranzin hydrate and ferulic acid were 139.53 min and 31.445 μg min/mL and 131.27 min and 14.835 μg min/mL, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[min·μg] / [ml],31.445,50795,DB00604,Cisapride
,21605652,area under the concentration-time curve from t=0 to the last time,"The elimination half-life and area under the concentration-time curve from t=0 to the last time of meranzin hydrate and ferulic acid were 139.53 min and 31.445 μg min/mL and 131.27 min and 14.835 μg min/mL, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[min·μg] / [ml],14.835,50796,DB00604,Cisapride
,21605652,absorption constant,"The absorption constant and volume of distribution of meranzin hydrate and ferulic acid were 0.185 ± 0.065 min(-1) and 3782.89 ± 2686.72 L/kg and 0.524 ± 0.157 min(-1) and 11713 ± 7618.68 L/kg, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),1/[min],0.185,50797,DB00604,Cisapride
,21605652,absorption constant,"The absorption constant and volume of distribution of meranzin hydrate and ferulic acid were 0.185 ± 0.065 min(-1) and 3782.89 ± 2686.72 L/kg and 0.524 ± 0.157 min(-1) and 11713 ± 7618.68 L/kg, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),1/[min],0.524,50798,DB00604,Cisapride
,21605652,volume of distribution,"The absorption constant and volume of distribution of meranzin hydrate and ferulic acid were 0.185 ± 0.065 min(-1) and 3782.89 ± 2686.72 L/kg and 0.524 ± 0.157 min(-1) and 11713 ± 7618.68 L/kg, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[l] / [kg],3782.89,50799,DB00604,Cisapride
,21605652,volume of distribution,"The absorption constant and volume of distribution of meranzin hydrate and ferulic acid were 0.185 ± 0.065 min(-1) and 3782.89 ± 2686.72 L/kg and 0.524 ± 0.157 min(-1) and 11713 ± 7618.68 L/kg, respectively.",Pharmacokinetic study of the prokinetic compounds meranzin hydrate and ferulic acid following oral administration of Chaihu-Shugan-San to patients with functional dyspepsia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21605652/),[l] / [kg],11713,50800,DB00604,Cisapride
,2900732,excretion of radioactivity,The excretion of radioactivity amounted to 97% within 4 days after a 1 mg/kg dose in dogs (72% in feces and 25% in urine).,Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,97,56848,DB00604,Cisapride
,2900732,excretion of radioactivity,The excretion of radioactivity amounted to 97% within 4 days after a 1 mg/kg dose in dogs (72% in feces and 25% in urine).,Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,72,56849,DB00604,Cisapride
,2900732,excretion of radioactivity,The excretion of radioactivity amounted to 97% within 4 days after a 1 mg/kg dose in dogs (72% in feces and 25% in urine).,Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,25,56850,DB00604,Cisapride
,2900732,Excretion,"Excretion of the parent drug was greater in dogs (0.4-1.3% of the dose in urine, 23% in feces) than in humans (0.2% in urine, 4-6% in feces).",Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),,0,56851,DB00604,Cisapride
,2900732,Excretion,"Excretion of the parent drug was greater in dogs (0.4-1.3% of the dose in urine, 23% in feces) than in humans (0.2% in urine, 4-6% in feces).",Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,23,56852,DB00604,Cisapride
,2900732,Excretion,"Excretion of the parent drug was greater in dogs (0.4-1.3% of the dose in urine, 23% in feces) than in humans (0.2% in urine, 4-6% in feces).",Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,0.2,56853,DB00604,Cisapride
,2900732,Excretion,"Excretion of the parent drug was greater in dogs (0.4-1.3% of the dose in urine, 23% in feces) than in humans (0.2% in urine, 4-6% in feces).",Excretion and biotransformation of cisapride in dogs and humans after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900732/),%,4-6,56854,DB00604,Cisapride
,1673393,half-life,"Comparable pharmacokinetic parameters were found in the lamb and the adult sheep: half-life, 1.39-1.83 hr; total plasma clearance, 1998-2160 ml/kg/hr; AUC, 92.6-100.1 ng.hr/ml.","Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),h,1.39-1.83,63100,DB00604,Cisapride
,1673393,total plasma clearance,"Comparable pharmacokinetic parameters were found in the lamb and the adult sheep: half-life, 1.39-1.83 hr; total plasma clearance, 1998-2160 ml/kg/hr; AUC, 92.6-100.1 ng.hr/ml.","Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),[ml] / [h·kg],1998-2160,63101,DB00604,Cisapride
,1673393,AUC,"Comparable pharmacokinetic parameters were found in the lamb and the adult sheep: half-life, 1.39-1.83 hr; total plasma clearance, 1998-2160 ml/kg/hr; AUC, 92.6-100.1 ng.hr/ml.","Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),[h·ng] / [ml],92.6-100.1,63102,DB00604,Cisapride
,1673393,fetal-to-maternal plasma concentration ratio,The average fetal-to-maternal plasma concentration ratio was 0.71.,"Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),,0.71,63103,DB00604,Cisapride
,1673393,protein binding,"The protein binding of cisapride in maternal and fetal plasma is 89.0% and 88.4%, respectively; the free fraction is 4 times larger than in humans.","Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),%,89.0,63104,DB00604,Cisapride
,1673393,protein binding,"The protein binding of cisapride in maternal and fetal plasma is 89.0% and 88.4%, respectively; the free fraction is 4 times larger than in humans.","Study of the placental transfer of cisapride in sheep. Plasma levels in the pregnant ewe, the fetus, and the lamb. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673393/),%,88.4,63105,DB00604,Cisapride
,9885965,systemic clearance (CI),"The mean (SD) values for systemic clearance (CI) and steady-state volume of distribution (Vss) were 494 (43.6) mL/h/kg and 1471 (578) mL/kg, respectively.",Pharmacokinetics of cisapride in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885965/),[ml] / [h·kg],494,79007,DB00604,Cisapride
,9885965,steady-state volume of distribution (Vss),"The mean (SD) values for systemic clearance (CI) and steady-state volume of distribution (Vss) were 494 (43.6) mL/h/kg and 1471 (578) mL/kg, respectively.",Pharmacokinetics of cisapride in the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885965/),[ml] / [kg],1471,79008,DB00604,Cisapride
,9885965,terminal half-life (t1/2),The average terminal half-life (t1/2) calculated over three i.g. doses was 2.06 h and that for i.v. administration was 2.12 h.,Pharmacokinetics of cisapride in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885965/),h,2.06,79009,DB00604,Cisapride
,9885965,terminal half-life (t1/2),The average terminal half-life (t1/2) calculated over three i.g. doses was 2.06 h and that for i.v. administration was 2.12 h.,Pharmacokinetics of cisapride in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885965/),h,2.12,79010,DB00604,Cisapride
,15619132,maximum concentration (C (max\ fit)),The tablets gave a maximum concentration (C (max\ fit)) of 0.43+/-0.14 mg/l at 2.37+/-1.20 h.,Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619132/),[mg] / [l],0.43,90485,DB00604,Cisapride
,15619132,C (max\ fit),"The C (max\ fit) of the oral solution of 0.60+/-0.17 mg/l was higher (P=0.0002) than that of the tablets, and interindividual variabilities of C (max\ fit) were 28% and 33%, respectively.",Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619132/),[mg] / [l],0.60,90486,DB00604,Cisapride
,9358420,maximum plasma drug concentration (Cmax),"After administration of the oral capsule, maximum plasma drug concentration (Cmax) +/- standard deviation (SD) was 73.32 +/- 16.59 ng/ml, and bioavailability +/- SD was 29.0 +/- 22.6%.",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),[ng] / [ml],73.32,93148,DB00604,Cisapride
,9358420,bioavailability,"After administration of the oral capsule, maximum plasma drug concentration (Cmax) +/- standard deviation (SD) was 73.32 +/- 16.59 ng/ml, and bioavailability +/- SD was 29.0 +/- 22.6%.",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),%,29.0,93149,DB00604,Cisapride
,9358420,peak cisapride concentration (C0),"Following i.v. administration, extrapolated peak cisapride concentration (C0) +/- SD was 421.30 +/- 155.37 ng/ml, and clearance +/- SD was 15 +/- 0.67 ml/kg per minute.",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),[ng] / [ml],421.30,93150,DB00604,Cisapride
,9358420,clearance,"Following i.v. administration, extrapolated peak cisapride concentration (C0) +/- SD was 421.30 +/- 155.37 ng/ml, and clearance +/- SD was 15 +/- 0.67 ml/kg per minute.",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),[ml] / [kg·min],15,93151,DB00604,Cisapride
,9358420,T1/2,"Elimination half-life (T1/2) was similar for both routes of administration (T1/2(oral) +/- SD was 5.27 +/- 3.16 hr, T1/2(i.v.) +/- SD was 5.19 +/- 3.77 hr).",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),h,5.27,93152,DB00604,Cisapride
,9358420,T1/2,"Elimination half-life (T1/2) was similar for both routes of administration (T1/2(oral) +/- SD was 5.27 +/- 3.16 hr, T1/2(i.v.) +/- SD was 5.19 +/- 3.77 hr).",Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358420/),h,5.19,93153,DB00604,Cisapride
,11864100,peak serum level,The mean peak serum level of cefetamet pivoxil in the placebo group was 4.86plus minus1.35 mg/L.,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),[mg] / [l],4.86,100752,DB00604,Cisapride
,11864100,elimination half-life,The elimination half-life was 3.56plus minus0.92 h.,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),p,3.56,100753,DB00604,Cisapride
,11864100,Cmax,The Cmax values differed significantly (p<0.05) only between the cisapride group (5.76plus minus1.50 mg/L) and the N-acetylcysteine group (4.53plus minus1.18 mg/L).,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),plus,5.76,100754,DB00604,Cisapride
,11864100,Cmax,The Cmax values differed significantly (p<0.05) only between the cisapride group (5.76plus minus1.50 mg/L) and the N-acetylcysteine group (4.53plus minus1.18 mg/L).,Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N-acetylcysteine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11864100/),plus,4.53,100755,DB00604,Cisapride
,14534518,time to reach peak plasma concentration (t(max)),"The pharmacokinetic parameters (mean +/- SD) were as follows: time to reach peak plasma concentration (t(max)), 4.4 +/- 2.8 hours (range, 0.9-12 hours); peak plasma concentration (C(max)), 29.3 +/- 16.6 ng/mL (range, 5.2-71.7 ng/mL); elimination half-life (t(1/2)), 10.7 +/- 3.7 hours (range, 1.9-18.1 hours); apparent total body clearance (Cl/F), 0.62 +/- 0.43 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),h,4.4,101250,DB00604,Cisapride
,14534518,peak plasma concentration (C(max)),"The pharmacokinetic parameters (mean +/- SD) were as follows: time to reach peak plasma concentration (t(max)), 4.4 +/- 2.8 hours (range, 0.9-12 hours); peak plasma concentration (C(max)), 29.3 +/- 16.6 ng/mL (range, 5.2-71.7 ng/mL); elimination half-life (t(1/2)), 10.7 +/- 3.7 hours (range, 1.9-18.1 hours); apparent total body clearance (Cl/F), 0.62 +/- 0.43 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[ng] / [ml],29.3,101251,DB00604,Cisapride
,14534518,elimination half-life (t(1/2)),"The pharmacokinetic parameters (mean +/- SD) were as follows: time to reach peak plasma concentration (t(max)), 4.4 +/- 2.8 hours (range, 0.9-12 hours); peak plasma concentration (C(max)), 29.3 +/- 16.6 ng/mL (range, 5.2-71.7 ng/mL); elimination half-life (t(1/2)), 10.7 +/- 3.7 hours (range, 1.9-18.1 hours); apparent total body clearance (Cl/F), 0.62 +/- 0.43 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),h,10.7,101252,DB00604,Cisapride
,14534518,apparent total body clearance (Cl/F),"The pharmacokinetic parameters (mean +/- SD) were as follows: time to reach peak plasma concentration (t(max)), 4.4 +/- 2.8 hours (range, 0.9-12 hours); peak plasma concentration (C(max)), 29.3 +/- 16.6 ng/mL (range, 5.2-71.7 ng/mL); elimination half-life (t(1/2)), 10.7 +/- 3.7 hours (range, 1.9-18.1 hours); apparent total body clearance (Cl/F), 0.62 +/- 0.43 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[l] / [h],0.62,101253,DB00604,Cisapride
,14534518,apparent volume of distribution (VD(ss)/F),"kg(-1)); and apparent volume of distribution (VD(ss)/F), 9.0 +/- 7.1 L/kg (range, 2.2-30.5 L/kg).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[l] / [kg],9.0,101254,DB00604,Cisapride
,14534518,apparent renal clearance (CL(R)),The apparent renal clearance (CL(R)) of cisapride in infants (n = 28) was estimated to be 0.003 +/- 0.003 L. h(-1).,Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[l] / [h],0.003,101255,DB00604,Cisapride
,14534518,C(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[ng] / [ml],44.5,101256,DB00604,Cisapride
,14534518,C(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[ng] / [ml],23.4,101257,DB00604,Cisapride
,14534518,C(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[ng] / [ml],30.0,101258,DB00604,Cisapride
,14534518,t(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),h,2.2,101259,DB00604,Cisapride
,14534518,t(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),h,4.4,101260,DB00604,Cisapride
,14534518,t(max),"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),h,5.0,101261,DB00604,Cisapride
,14534518,CL/F,"Substratification of the population based on postconceptional age demonstrated the following findings for cisapride: (1) The mean (+/-SD) C(max) for cisapride was higher in the oldest postconceptional age category (44.5 +/- 19.6 ng/mL) than the middle and youngest categories (23.4 +/- 11.7 ng/mL and 30.0 +/- 17.5 ng/mL, respectively); (2) the t(max) for cisapride was shortest in the oldest postconceptional age category (2.2 +/- 1.1 hours) compared with the middle and youngest categories (4.4 +/- 3.3 hours and 5.0 +/- 2.6 hours, respectively); (3) the CL/F for cisapride in the youngest postconceptional age group was significantly lower (0.45 +/- 0.26 L. h(-1).",Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534518/),[l] / [h],0.45,101262,DB00604,Cisapride
,9643622,time at which maximum serum concentrations were reached (tmax),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,2.79,119237,DB00604,Cisapride
,9643622,time at which maximum serum concentrations were reached (tmax),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,1.16,119238,DB00604,Cisapride
,9643622,absorption rate constant (ka),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],0.49,119239,DB00604,Cisapride
,9643622,absorption rate constant (ka),"The addition of cisapride decreased the time at which maximum serum concentrations were reached (tmax) from 2.79 (1.85-4.34) h to 1.16 (0.68-2.30) h (P=0.009) [95% CI: -2.59, -0.55] and increased the absorption rate constant (ka) from 0.49 (0.31-0.69) h(-1) to 1.26 (0.52-5.61) h(-1) (P=0.017).",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],1.26,119240,DB00604,Cisapride
,9643622,absolute bioavailability,"The absolute bioavailability of sotalol was reduced by cisapride from 1.00+/-0.15 to 0.70+/-0.26 (P=0.006), while maximum serum concentrations of both oral solutions were not significantly different.",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),,1.00,119241,DB00604,Cisapride
,9643622,absolute bioavailability,"The absolute bioavailability of sotalol was reduced by cisapride from 1.00+/-0.15 to 0.70+/-0.26 (P=0.006), while maximum serum concentrations of both oral solutions were not significantly different.",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),,0.70,119242,DB00604,Cisapride
,9643622,tmax,"Compared with the sublingually administered tablet with a median tmax of 2.12 (0.89-3.28) h, the sotalol/cisapride oral solution gave a smaller tmax (p=0.009) [95% CI: -1.64, -0.36].",Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),h,2.12,119243,DB00604,Cisapride
,9643622,ka,The ka of the sotalol/cisapride solution was significantly (P=0.010) larger than the ka of 0.56 (0.33-0.75) h(-1) found after sublingual administration of the tablet.,Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643622/),1/[h],0.56,119244,DB00604,Cisapride
,3435588,plasma clearance (ClT),The plasma clearance (ClT) and volume of distribution (Vdss) averaged 91 ml/min.,"Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435588/),[ml] / [min],91,129057,DB00604,Cisapride
,3435588,absolute bioavailability,"Compared with intravenous administration, the absolute bioavailability of oral cisapride was 23% in rats and 53% in the dog for the drug given in solution.","Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435588/),%,23,129058,DB00604,Cisapride
,3435588,absolute bioavailability,"Compared with intravenous administration, the absolute bioavailability of oral cisapride was 23% in rats and 53% in the dog for the drug given in solution.","Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435588/),%,53,129059,DB00604,Cisapride
,3435588,terminal plasma half-life,The terminal plasma half-life of cisapride was about 1-2 h in the rat and about 4-10 h in the rabbit and dog.,"Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435588/),h,1-2,129060,DB00604,Cisapride
,3435588,terminal plasma half-life,The terminal plasma half-life of cisapride was about 1-2 h in the rat and about 4-10 h in the rabbit and dog.,"Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435588/),h,4-10,129061,DB00604,Cisapride
,3582418,peak plasma concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.5,131947,DB00604,Cisapride
,3582418,peak plasma concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.1,131948,DB00604,Cisapride
,3582418,peak concentration,"Metoclopramide reduced the peak plasma concentration of digoxin from 1.5 +/- 0.2 ng/ml to 1.1 +/- 0.1 ng/ml (mean +/- SEM) (p = 0.05), cisapride lowered the peak concentration to 1.3 +/- 0.1 ng/ml (p = 0.14).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [ml],1.3,131949,DB00604,Cisapride
,3582418,time required to reach the peak concentration,"Metoclopramide prolonged the time required to reach the peak concentration of digoxin from 2 hr to 2.7 hr (p = 0.17), cisapride did not.",Effect of cisapride and metoclopramide on digoxin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),h,2,131950,DB00604,Cisapride
,3582418,time required to reach the peak concentration,"Metoclopramide prolonged the time required to reach the peak concentration of digoxin from 2 hr to 2.7 hr (p = 0.17), cisapride did not.",Effect of cisapride and metoclopramide on digoxin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),h,2.7,131951,DB00604,Cisapride
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],743,131952,DB00604,Cisapride
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],653,131953,DB00604,Cisapride
,3582418,AUC0-12,"Digoxin AUC0-12 (743 +/- 79 ng/ml.min) was reduced by 12% on coadministration of cisapride (653 +/- 38 ng/ml.min, p = 0.22) and by 19% on coadministration of metoclopramide (605 +/- 34 ng/ml.min, p = 0.06).",Effect of cisapride and metoclopramide on digoxin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582418/),[ng] / [min·ml],605,131954,DB00604,Cisapride
,9118661,area under the acetam,There was no significant change in the area under the acetaminophen absorption curve from 0 to 60 mins from day 1 to day 2 in patients who received placebo or cisapride.,"Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,0,132600,DB00604,Cisapride
,9118661,area under the acetam,There was no significant change in the area under the acetaminophen absorption curve from 0 to 60 mins from day 1 to day 2 in patients who received placebo or cisapride.,"Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,60,132601,DB00604,Cisapride
< or =,9118661,time to maximum acetaminophen concentration,"Using the combination of the time to maximum acetaminophen concentration (< or = 30 mins) with a maximum concentration (> 12 mg/L) to define ""normal"" emptying, on day 1, four of the 11 placebo patients had the ""normal"" gastric emptying, and by day 2, five patients fulfilled this criterion.","Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),min,30,132602,DB00604,Cisapride
>,9118661,maximum concentration,"Using the combination of the time to maximum acetaminophen concentration (< or = 30 mins) with a maximum concentration (> 12 mg/L) to define ""normal"" emptying, on day 1, four of the 11 placebo patients had the ""normal"" gastric emptying, and by day 2, five patients fulfilled this criterion.","Double-blind, randomized study of the effect of cisapride on gastric emptying in critically ill patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9118661/),[mg] / [l],12,132603,DB00604,Cisapride
,11728962,heart rates,"In included patients (6 men, 8 women), heart rates were 86.71 +/- 20.87 beats/min at baseline and 86.57 +/- 14.23 beats/min during treatment (P = not significant).",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),[beats] / [min],86.71,137440,DB00604,Cisapride
,11728962,heart rates,"In included patients (6 men, 8 women), heart rates were 86.71 +/- 20.87 beats/min at baseline and 86.57 +/- 14.23 beats/min during treatment (P = not significant).",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),[beats] / [min],86.57,137441,DB00604,Cisapride
,11728962,QT(max),"Average baseline QT(max) and QT(min) were 391.07 +/- 42.43 and 330.71 +/- 40.94 milliseconds, respectively.",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),mill,391.07,137442,DB00604,Cisapride
,11728962,QT(min),"Average baseline QT(max) and QT(min) were 391.07 +/- 42.43 and 330.71 +/- 40.94 milliseconds, respectively.",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),mill,330.71,137443,DB00604,Cisapride
,11728962,QT(max),"Treatment QT(max) and QT(min) were 391.43 +/- 38.2 and 343.93 +/- 35.69 milliseconds, respectively (P = not significant for both).",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),milliseconds,391.43,137444,DB00604,Cisapride
,11728962,QT(min),"Treatment QT(max) and QT(min) were 391.43 +/- 38.2 and 343.93 +/- 35.69 milliseconds, respectively (P = not significant for both).",Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),milliseconds,343.93,137445,DB00604,Cisapride
,11728962,QTD,QTD was 60.36 +/- 17.59 milliseconds at baseline and 47.5 +/- 19.59 milliseconds during treatment (P = 0.074).,Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),mill,60.36,137446,DB00604,Cisapride
,11728962,QTD,QTD was 60.36 +/- 17.59 milliseconds at baseline and 47.5 +/- 19.59 milliseconds during treatment (P = 0.074).,Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),mill,47.5,137447,DB00604,Cisapride
,11728962,corrected QT (QTc) intervals,Mean corrected QT (QTc) intervals increased from 426.57 +/- 26.62 to 431.71 +/- 29.98 milliseconds (P = 0.55) from baseline to treatment.,Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),millise,426.57,137448,DB00604,Cisapride
,11728962,corrected QT (QTc) intervals,Mean corrected QT (QTc) intervals increased from 426.57 +/- 26.62 to 431.71 +/- 29.98 milliseconds (P = 0.55) from baseline to treatment.,Retrospective analysis of the effects of cisapride on the QT interval and QT dispersion in chronic hemodialysis patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11728962/),millise,431.71,137449,DB00604,Cisapride
,12451427,absorption constant rate,The absorption constant rate was fixed to 2.5 h-1.,Population pharmacokinetics of cisapride in neonates. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451427/),1/[h],2.5,146213,DB00604,Cisapride
,12451427,V/F,"Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).",Population pharmacokinetics of cisapride in neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451427/),ml,"17,200",146214,DB00604,Cisapride
,12451427,CL/F,"Final population pharmacokinetic parameters (interindividual variability) were: V/F=17,200 mL (90.4%) and CL/F=3.91 x WT(3/4) mL/h (36.3%).",Population pharmacokinetics of cisapride in neonates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451427/),[ml] / [h],3.91,146215,DB00604,Cisapride
,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,500.43,147763,DB00604,Cisapride
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,167.09,147764,DB00604,Cisapride
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,166.04,147765,DB00604,Cisapride
>,20099369,m/z,Acquisition was performed in multiple-reaction monitoring mode by monitoring the transitions: m/z 500.43 > 167.09 for carebastine and m/z 166.04 > 147.88 for pseudoephedrine.,Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20099369/),,147.88,147766,DB00604,Cisapride
,11480539,area under the plasma paracetamol concentration-time curve from 0 to 180 min,The area under the plasma paracetamol concentration-time curve from 0 to 180 min (mean +/- s.d.) increased from 1875.0 +/- 112.8 micrg min mL(-1) (placebo coadministration) to 2238.8 +/- 125.8 microg min mL(-1) (cisapride coadministration) (P < 0.01).,Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[micrg·min] / [ml],1875.0,154696,DB00604,Cisapride
,11480539,area under the plasma paracetamol concentration-time curve from 0 to 180 min,The area under the plasma paracetamol concentration-time curve from 0 to 180 min (mean +/- s.d.) increased from 1875.0 +/- 112.8 micrg min mL(-1) (placebo coadministration) to 2238.8 +/- 125.8 microg min mL(-1) (cisapride coadministration) (P < 0.01).,Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[min·μg] / [ml],2238.8,154697,DB00604,Cisapride
,11480539,maximum plasma paracetamol concentration,"The mean maximum plasma paracetamol concentration(18.2 microg mL(-1))with placebo was reached 30 min after administration, whereas mean maximum plasma paracetamol concentration (21.2 microg mL(-1)) with cisapride occurred 45 min after administration.",Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[μg] / [ml],18.2,154698,DB00604,Cisapride
,11480539,maximum plasma paracetamol concentration,"The mean maximum plasma paracetamol concentration(18.2 microg mL(-1))with placebo was reached 30 min after administration, whereas mean maximum plasma paracetamol concentration (21.2 microg mL(-1)) with cisapride occurred 45 min after administration.",Cisapride raises the bioavailability of paracetamol by inhibiting its glucuronidation in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11480539/),[μg] / [ml],21.2,154699,DB00604,Cisapride
,9842980,AUC0-infinity,"The pharmacokinetic parameter values (mean+/-RSD%) of cisapride as the test formulation were: AUC0-infinity=329+/-20.9 ng.h/ml, Cmax=52.8+/-22.6 ng/ml, tmax=1.26+/-22.0 h and t1/2=4.08+/-15 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),[h·ng] / [ml],329,155658,DB00604,Cisapride
,9842980,Cmax,"The pharmacokinetic parameter values (mean+/-RSD%) of cisapride as the test formulation were: AUC0-infinity=329+/-20.9 ng.h/ml, Cmax=52.8+/-22.6 ng/ml, tmax=1.26+/-22.0 h and t1/2=4.08+/-15 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),[ng] / [ml],52.8,155659,DB00604,Cisapride
,9842980,tmax,"The pharmacokinetic parameter values (mean+/-RSD%) of cisapride as the test formulation were: AUC0-infinity=329+/-20.9 ng.h/ml, Cmax=52.8+/-22.6 ng/ml, tmax=1.26+/-22.0 h and t1/2=4.08+/-15 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),h,1.26,155660,DB00604,Cisapride
,9842980,t1/2,"The pharmacokinetic parameter values (mean+/-RSD%) of cisapride as the test formulation were: AUC0-infinity=329+/-20.9 ng.h/ml, Cmax=52.8+/-22.6 ng/ml, tmax=1.26+/-22.0 h and t1/2=4.08+/-15 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),h,4.08,155661,DB00604,Cisapride
,9842980,AUC0-infinity,"Following administration of the reference formulation the values obtained for the same parameters were: AUC0-infinity=317+/-19.2 ng.h/ml, Cmax=49.2+/-21.3 ng/ml, tmax=1.38+/-30.1 h and t1/2=4.52+/-24.8 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),[h·ng] / [ml],317,155662,DB00604,Cisapride
,9842980,Cmax,"Following administration of the reference formulation the values obtained for the same parameters were: AUC0-infinity=317+/-19.2 ng.h/ml, Cmax=49.2+/-21.3 ng/ml, tmax=1.38+/-30.1 h and t1/2=4.52+/-24.8 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),[ng] / [ml],49.2,155663,DB00604,Cisapride
,9842980,tmax,"Following administration of the reference formulation the values obtained for the same parameters were: AUC0-infinity=317+/-19.2 ng.h/ml, Cmax=49.2+/-21.3 ng/ml, tmax=1.38+/-30.1 h and t1/2=4.52+/-24.8 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),h,1.38,155664,DB00604,Cisapride
,9842980,t1/2,"Following administration of the reference formulation the values obtained for the same parameters were: AUC0-infinity=317+/-19.2 ng.h/ml, Cmax=49.2+/-21.3 ng/ml, tmax=1.38+/-30.1 h and t1/2=4.52+/-24.8 h.",Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842980/),h,4.52,155665,DB00604,Cisapride
,10471987,peak concentration (Cmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[ng] / [ml],56,155744,DB00604,Cisapride
,10471987,time to Cmax (tmax),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,1.7,155745,DB00604,Cisapride
,10471987,area under the concentration-time curve (AUC),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),[h·ng] / [ml],426,155746,DB00604,Cisapride
,10471987,terminal half-life (t1/2),"For cisapride alone, mean parameter values were the following: peak concentration (Cmax), 56 ng/mL; time to Cmax (tmax), 1.7 hours; area under the concentration-time curve (AUC), 426 ng x h/mL; and terminal half-life (t1/2), 5.8 hours.",Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10471987/),h,5.8,155747,DB00604,Cisapride
,10594470,CL/F,"The typical population values of CL/F, V /F and Ka (absorption rate constant) were 0.538 l h-1 kg-1, 21.9 l, and 2.58 h-1, respectively.",Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594470/),[l] / [h·kg],0.538,157688,DB00604,Cisapride
,10594470,V /F,"The typical population values of CL/F, V /F and Ka (absorption rate constant) were 0.538 l h-1 kg-1, 21.9 l, and 2.58 h-1, respectively.",Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594470/),l,21.9,157689,DB00604,Cisapride
,10594470,Ka (absorption rate constant),"The typical population values of CL/F, V /F and Ka (absorption rate constant) were 0.538 l h-1 kg-1, 21.9 l, and 2.58 h-1, respectively.",Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594470/),1/[h],2.58,157690,DB00604,Cisapride
,1752111,terminal half-life,"After a single oral dose of 20 mg the terminal half-life of cisapride was 9.6 +/- 3.3 hours, the volume of distribution was 4.8 +/- 3.3 L/kg, the total oral plasma clearance was 380 +/- 161 ml/min, the area under the curve was 1024 +/- 447 ng.hr/ml (mean +/- SD).",Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752111/),h,9.6,157942,DB00604,Cisapride
,1752111,volume of distribution,"After a single oral dose of 20 mg the terminal half-life of cisapride was 9.6 +/- 3.3 hours, the volume of distribution was 4.8 +/- 3.3 L/kg, the total oral plasma clearance was 380 +/- 161 ml/min, the area under the curve was 1024 +/- 447 ng.hr/ml (mean +/- SD).",Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752111/),[l] / [kg],4.8,157943,DB00604,Cisapride
,1752111,total oral plasma clearance,"After a single oral dose of 20 mg the terminal half-life of cisapride was 9.6 +/- 3.3 hours, the volume of distribution was 4.8 +/- 3.3 L/kg, the total oral plasma clearance was 380 +/- 161 ml/min, the area under the curve was 1024 +/- 447 ng.hr/ml (mean +/- SD).",Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752111/),[ml] / [min],380,157944,DB00604,Cisapride
,1752111,area under the curve,"After a single oral dose of 20 mg the terminal half-life of cisapride was 9.6 +/- 3.3 hours, the volume of distribution was 4.8 +/- 3.3 L/kg, the total oral plasma clearance was 380 +/- 161 ml/min, the area under the curve was 1024 +/- 447 ng.hr/ml (mean +/- SD).",Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752111/),[h·ng] / [ml],1024,157945,DB00604,Cisapride
,1752111,clearance,Norcisapride only could be detected in the dialysate (0.36 +/- 0.067 mg) and was eliminated by a hemodialysis clearance of 34.7 +/- 7.9 ml/min.,Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1752111/),[ml] / [min],34.7,157946,DB00604,Cisapride
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00604,Cisapride
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00604,Cisapride
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00604,Cisapride
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00604,Cisapride
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00604,Cisapride
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00604,Cisapride
,3709647,t 1/2,"Cisapride increased the rate of gastric emptying of 500 ml liquid containing diazepam 10 mg (t 1/2 C: 7.4 min, P: 14.9 min).",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),min,7.4,170681,DB00604,Cisapride
,3709647,t 1/2,"Cisapride increased the rate of gastric emptying of 500 ml liquid containing diazepam 10 mg (t 1/2 C: 7.4 min, P: 14.9 min).",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),min,14.9,170682,DB00604,Cisapride
,3709647,AUC 0-1 h,"The initial rate of absorption of diazepam contained in the drink was increased by C (AUC 0-1 h C: 328 micrograms h l-1, P: 253 micrograms h l-1, but there was no change in overall bioavailability.",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),[h·μg] / [l],328,170683,DB00604,Cisapride
,3709647,AUC 0-1 h,"The initial rate of absorption of diazepam contained in the drink was increased by C (AUC 0-1 h C: 328 micrograms h l-1, P: 253 micrograms h l-1, but there was no change in overall bioavailability.",The action of cisapride on gastric emptying and the pharmacodynamics and pharmacokinetics of oral diazepam. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709647/),[h·μg] / [l],253,170684,DB00604,Cisapride
,12682804,concentration,"Mean concentration of cisapride 1 h after administration was, as expected from the dosing regimen, significantly higher in group A than in group B (123.7+/-43.2 ng/ml versus 86.7+/-27.8 ng/ml; P=0.03).",A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682804/),ng,123,180810,DB00604,Cisapride
,12682804,concentration,"Mean concentration of cisapride 1 h after administration was, as expected from the dosing regimen, significantly higher in group A than in group B (123.7+/-43.2 ng/ml versus 86.7+/-27.8 ng/ml; P=0.03).",A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682804/),[ng] / [ml],86.7,180811,DB00604,Cisapride
,12682804,trough concentration,The difference in trough concentration was not significant (107.4+/-44.3 ng/ml versus 78.2+/-35.4 ng/ml; P=0.09).,A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682804/),[ng] / [ml],107.4,180812,DB00604,Cisapride
,12682804,trough concentration,The difference in trough concentration was not significant (107.4+/-44.3 ng/ml versus 78.2+/-35.4 ng/ml; P=0.09).,A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682804/),[ng] / [ml],78.2,180813,DB00604,Cisapride
,9257738,maximum concentration of drug in serum (C(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.27,181234,DB00604,Cisapride
,9257738,time to C(max) (T(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,4.1,181235,DB00604,Cisapride
,9257738,area under the concentration-time curve (AUC),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],35.0,181236,DB00604,Cisapride
,9257738,mean residence time,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,28.5,181237,DB00604,Cisapride
,9257738,half-life (t1/2),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,20,181238,DB00604,Cisapride
,9257738,urinary recovery (UR x f),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,11.0,181239,DB00604,Cisapride
,9257738,ratio,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),,2.6,181240,DB00604,Cisapride
,9257738,T(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,1.9,181241,DB00604,Cisapride
,9257738,C(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.74,181242,DB00604,Cisapride
,9257738,C(max),"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],0.77,181243,DB00604,Cisapride
,9257738,AUC,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],18.6,181244,DB00604,Cisapride
,9257738,t1/2,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,26,181245,DB00604,Cisapride
,9257738,UR x f,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,5.8,181246,DB00604,Cisapride
,2373139,time to the peak plasma concentration,"The 30 mg suppository exhibited a mean time to the peak plasma concentration of 3.8 h, while the tablets showed a significantly earlier peak time of 1.5 h.",Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),h,3.8,191677,DB00604,Cisapride
,2373139,peak time,"The 30 mg suppository exhibited a mean time to the peak plasma concentration of 3.8 h, while the tablets showed a significantly earlier peak time of 1.5 h.",Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),h,1.5,191678,DB00604,Cisapride
,2373139,maximum plasma concentration,The maximum plasma concentration of cisapride after the 30 mg suppository (50.3 ng.,Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),ng,50.3,191679,DB00604,Cisapride
,2373139,bioavailability,"The comparative bioavailability of the 30 mg cisapride suppository in relation to the three 5 mg oral tablets was 85%, with a 95%-confidence interval of 67% to 102% (not adjusted for dose).",Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),%,85,191680,DB00604,Cisapride
,2373139,relative bioavailability,"Normalizing the mean AUC by dose, the relative bioavailability of the suppository was 43% of that of the tablet.",Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),%,43,191681,DB00604,Cisapride
,2373139,elimination half-life,The elimination half-life of cisapride was not significantly different following the administration of the two formulations (9.3 h for the suppository and 9.8 h for the tablet).,Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),h,9.3,191682,DB00604,Cisapride
,2373139,elimination half-life,The elimination half-life of cisapride was not significantly different following the administration of the two formulations (9.3 h for the suppository and 9.8 h for the tablet).,Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373139/),h,9.8,191683,DB00604,Cisapride
,11678783,Cmax,"In control (water treated) subjects, the mean Cmax (30 +/- 13.6 ng ml-1; P = 0.0008) and AUC(0, infinity) (201 +/- 161 ng ml-1 h; P = 0.029) of (-)-cisapride were significantly higher than the Cmax (10.5 +/- 3.4 ng ml-1) and AUC(0, infinity) (70 +/- 51.5 ng ml-1 h) of (+)-cisapride.",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],30,202743,DB00604,Cisapride
,11678783,"AUC(0, infinity)","In control (water treated) subjects, the mean Cmax (30 +/- 13.6 ng ml-1; P = 0.0008) and AUC(0, infinity) (201 +/- 161 ng ml-1 h; P = 0.029) of (-)-cisapride were significantly higher than the Cmax (10.5 +/- 3.4 ng ml-1) and AUC(0, infinity) (70 +/- 51.5 ng ml-1 h) of (+)-cisapride.",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],201,202744,DB00604,Cisapride
,11678783,Cmax,"In control (water treated) subjects, the mean Cmax (30 +/- 13.6 ng ml-1; P = 0.0008) and AUC(0, infinity) (201 +/- 161 ng ml-1 h; P = 0.029) of (-)-cisapride were significantly higher than the Cmax (10.5 +/- 3.4 ng ml-1) and AUC(0, infinity) (70 +/- 51.5 ng ml-1 h) of (+)-cisapride.",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],10.5,202745,DB00604,Cisapride
,11678783,"AUC(0, infinity)","In control (water treated) subjects, the mean Cmax (30 +/- 13.6 ng ml-1; P = 0.0008) and AUC(0, infinity) (201 +/- 161 ng ml-1 h; P = 0.029) of (-)-cisapride were significantly higher than the Cmax (10.5 +/- 3.4 ng ml-1) and AUC(0, infinity) (70 +/- 51.5 ng ml-1 h) of (+)-cisapride.",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],70,202746,DB00604,Cisapride
,11678783,elimination half-life,There was no marked difference in elimination half-life between (-)-cisapride (4.7 +/- 2.7 h) and (+)-cisapride (4.8 +/- 3 h).,Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),h,4.7,202747,DB00604,Cisapride
,11678783,elimination half-life,There was no marked difference in elimination half-life between (-)-cisapride (4.7 +/- 2.7 h) and (+)-cisapride (4.8 +/- 3 h).,Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),h,4.8,202748,DB00604,Cisapride
,11678783,Cmax,"Compared with the water treated group, grapefruit juice significantly increased the mean Cmax of (-)-cisapride from 30 +/- 13.6-55.5 +/- 18 ng ml-1 (95% CI on mean difference, -33, -17; P = 0.00005) and of (+)-cisapride from 10.5 +/- 3.4 to 18.4 +/- 6.2 ng ml-1 (95% CI on mean difference, -11.8, -3.9, P = 0.00015).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],30,202749,DB00604,Cisapride
,11678783,Cmax,"Compared with the water treated group, grapefruit juice significantly increased the mean Cmax of (-)-cisapride from 30 +/- 13.6-55.5 +/- 18 ng ml-1 (95% CI on mean difference, -33, -17; P = 0.00005) and of (+)-cisapride from 10.5 +/- 3.4 to 18.4 +/- 6.2 ng ml-1 (95% CI on mean difference, -11.8, -3.9, P = 0.00015).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],55.5,202750,DB00604,Cisapride
,11678783,Cmax,"Compared with the water treated group, grapefruit juice significantly increased the mean Cmax of (-)-cisapride from 30 +/- 13.6-55.5 +/- 18 ng ml-1 (95% CI on mean difference, -33, -17; P = 0.00005) and of (+)-cisapride from 10.5 +/- 3.4 to 18.4 +/- 6.2 ng ml-1 (95% CI on mean difference, -11.8, -3.9, P = 0.00015).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],10.5,202751,DB00604,Cisapride
,11678783,Cmax,"Compared with the water treated group, grapefruit juice significantly increased the mean Cmax of (-)-cisapride from 30 +/- 13.6-55.5 +/- 18 ng ml-1 (95% CI on mean difference, -33, -17; P = 0.00005) and of (+)-cisapride from 10.5 +/- 3.4 to 18.4 +/- 6.2 ng ml-1 (95% CI on mean difference, -11.8, -3.9, P = 0.00015).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[ng] / [ml],18.4,202752,DB00604,Cisapride
,11678783,"AUC(0, infinity)","The mean AUC(0, infinity) of (-)-cisapride was increased from 201 +/- 161 to 521.6 +/- 303 ng ml-1 h (95% CI on mean difference, -439, -202; P = 0.0002) and that of (+)-cisapride from 70 +/- 51.5 to 170 +/- 91 ng ml-1 h (95% CI on mean difference, -143, -53; P = 0.0005).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],201,202753,DB00604,Cisapride
,11678783,"AUC(0, infinity)","The mean AUC(0, infinity) of (-)-cisapride was increased from 201 +/- 161 to 521.6 +/- 303 ng ml-1 h (95% CI on mean difference, -439, -202; P = 0.0002) and that of (+)-cisapride from 70 +/- 51.5 to 170 +/- 91 ng ml-1 h (95% CI on mean difference, -143, -53; P = 0.0005).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],521.6,202754,DB00604,Cisapride
,11678783,"AUC(0, infinity)","The mean AUC(0, infinity) of (-)-cisapride was increased from 201 +/- 161 to 521.6 +/- 303 ng ml-1 h (95% CI on mean difference, -439, -202; P = 0.0002) and that of (+)-cisapride from 70 +/- 51.5 to 170 +/- 91 ng ml-1 h (95% CI on mean difference, -143, -53; P = 0.0005).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],70,202755,DB00604,Cisapride
,11678783,"AUC(0, infinity)","The mean AUC(0, infinity) of (-)-cisapride was increased from 201 +/- 161 to 521.6 +/- 303 ng ml-1 h (95% CI on mean difference, -439, -202; P = 0.0002) and that of (+)-cisapride from 70 +/- 51.5 to 170 +/- 91 ng ml-1 h (95% CI on mean difference, -143, -53; P = 0.0005).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),[h·ng] / [ml],170,202756,DB00604,Cisapride
,11678783,tmax,"The tmax was also significantly increased for both enantiomers (from 1.35 to 2.8 h for (-)-cisapride and from 1.75 to 2.9 h for (+)-cisapride in the control and grapefruit juice group, respectively; P < 0.05).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),h,1.35 to 2.8,202757,DB00604,Cisapride
,11678783,tmax,"The tmax was also significantly increased for both enantiomers (from 1.35 to 2.8 h for (-)-cisapride and from 1.75 to 2.9 h for (+)-cisapride in the control and grapefruit juice group, respectively; P < 0.05).",Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678783/),h,1.75 to 2.9,202758,DB00604,Cisapride
,11568520,QTc interval,The QTc interval increased significantly from 423 ms to 461 ms after 72 hours of treatment (P = 0.0007).,The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568520/),ms,423,202925,DB00604,Cisapride
,11568520,QTc interval,The QTc interval increased significantly from 423 ms to 461 ms after 72 hours of treatment (P = 0.0007).,The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568520/),ms,461,202926,DB00604,Cisapride
,11568520,dispersion,No effect was seen on QT dispersion (44.3 ms vs. 45.9 ms).,The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568520/),ms,44.3,202927,DB00604,Cisapride
,11568520,dispersion,No effect was seen on QT dispersion (44.3 ms vs. 45.9 ms).,The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11568520/),ms,45.9,202928,DB00604,Cisapride
,3691010,peak plasma concentrations,"There was a significant difference in mean peak plasma concentrations between treatment A (48.8 +/- 12.8 ng/mL) and treatment D (41.6 +/- 10.6 ng/mL), with treatment A producing a 17.3% higher peak concentration.","Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691010/),[ng] / [ml],48.8,216618,DB00604,Cisapride
,3691010,peak plasma concentrations,"There was a significant difference in mean peak plasma concentrations between treatment A (48.8 +/- 12.8 ng/mL) and treatment D (41.6 +/- 10.6 ng/mL), with treatment A producing a 17.3% higher peak concentration.","Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691010/),[ng] / [ml],41.6,216619,DB00604,Cisapride
,3691010,elimination half-life,The overall mean elimination half-life was 7.01 hours.,"Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691010/),h,7.01,216620,DB00604,Cisapride
,18401863,LOQ,The LOQ for doxazosin was 0.2 ng/mL using 100 microL plasma sample.,Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),[ng] / [ml],0.2,217179,DB00604,Cisapride
,18401863,recoveries,"The recoveries of doxazosin and cisapride were 67.4 and 61.7%, respectively.",Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),%,67.4,217180,DB00604,Cisapride
,18401863,recoveries,"The recoveries of doxazosin and cisapride were 67.4 and 61.7%, respectively.",Quantification of doxazosin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18401863/),%,61.7,217181,DB00604,Cisapride
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],3.8,219529,DB00604,Cisapride
,10594475,maximum blood-ethanol concentration (Cmax ),The maximum blood-ethanol concentration (Cmax ) increased from 3.8+/-1.7 to 5.6+/-2.3 mmol l-1 (+/-s.d.) after treatment with cisapride (95% confidence interval CI on mean difference 0.28-3.28 mmol l-1 ).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],5.6,219530,DB00604,Cisapride
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],6.3,219531,DB00604,Cisapride
,10594475,area under the blood-ethanol curve (AUC),The area under the blood-ethanol curve (AUC) increased from 6.3+/-3.5 to 7.9+/-2.6 mmol l-1 h after cisapride (95% CI -0. 74-3.9 mmol l-1 h).,Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],7.9,219532,DB00604,Cisapride
,10594475,Cmax,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[mM] / [l],9.5,219533,DB00604,Cisapride
,10594475,AUC,"Both Cmax and AUC were highest when the ethanol was ingested on an empty stomach (Cmax 9.5+/-1.7 mmol l-1 and AUC 14. 6+/-1.9 mmol l-1 h), compared with drinking 1 h after a meal and regardless of pretreatment with cisapride.",Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594475/),[h·mM] / [l],14. 6,219534,DB00604,Cisapride
,9726696,elimination half-life,"The obtained elimination half-life averaged 21.8+/-10.6 hours, which seems to be considerably longer than those previously reported.",Pharmacokinetic characteristics of cisapride in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9726696/),h,21.8,238230,DB00604,Cisapride
,17416379,flow rate,"At a flow rate of 1 ml/min, the total run time was 18 min.",Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17416379/),[ml] / [min],1,244568,DB00604,Cisapride
,17416379,total run time,"At a flow rate of 1 ml/min, the total run time was 18 min.",Development and validation of a high-performance liquid chromatographic method using fluorescence detection for the determination of vardenafil in small volumes of rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17416379/),min,18,244569,DB00604,Cisapride
,2741189,peak plasma concentration,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [ml],58,260864,DB00604,Cisapride
,2741189,peak plasma concentration,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [ml],84,260865,DB00604,Cisapride
,2741189,AUC0-24,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [h·ml],509,260866,DB00604,Cisapride
,2741189,AUC0-24,Cimetidine increased the cisapride peak plasma concentration from 58 +/- 25 ng/ml to 84 +/- 19 ng/ml (p = 0.01) and AUC0-24 from 509 +/- 289 ng/ml.h to 738 +/- 148 ng/ml.h (p = 0.02).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[ng] / [h·ml],738,260867,DB00604,Cisapride
,2741189,time to the peak concentration,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),h,1.3,260868,DB00604,Cisapride
,2741189,time to the peak concentration,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),h,0.6,260869,DB00604,Cisapride
,2741189,AUC0-24,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[μg] / [h·ml],11.0,260870,DB00604,Cisapride
,2741189,AUC0-24,Cisapride shortened the time to the peak concentration of cimetidine from 1.3 +/- 0.6 h to 0.6 +/- 0.2 h (p = 0.005) and reduced the cimetidine AUC0-24 from 11.0 +/- 2.3 micrograms/ml.h to 9.0 +/- 2.0 micrograms/ml.h (p = 0.05).,Cisapride-cimetidine interaction: enhanced cisapride bioavailability and accelerated cimetidine absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2741189/),[μg] / [h·ml],9.0,260871,DB00604,Cisapride
,10223776,maximum measured plasma concentration (Cmax,"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[ng] / [ml],65,268365,DB00604,Cisapride
,10223776,maximum measured plasma concentration (Cmax,"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[ng] / [ml],87,268366,DB00604,Cisapride
,10223776,area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25),"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[h·ng] / [ml],418,268367,DB00604,Cisapride
,10223776,area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25),"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[h·ng] / [ml],580,268368,DB00604,Cisapride
,10223776,time to reach Cmax,"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),h,1.26,268369,DB00604,Cisapride
,10223776,time to reach Cmax,"Grapefruit juice increased cisapride maximum measured plasma concentration (Cmax; water, 65+/-398 ng/mL; grapefruit juice, 87+/-40 ng/mL; P = .009) and area under the plasma concentration-time curve from 0 to 25 hours [AUC(0-25); water, 418+/-280 h x ng/mL; grapefruit juice, 580+/-289 h x ng/mL; P = .005] and prolonged the time to reach Cmax (water, 1.26+/-0.36 hours; grapefruit juice, 1.72+/-0.55 hours; P = .02).",Influence of grapefruit juice on cisapride pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),h,1.72,268370,DB00604,Cisapride
,10223776,partial apparent metabolic clearance,Urinary norcisapride recovery was similar and thus the partial apparent metabolic clearance to norcisapride was lower (P = .046) after grapefruit juice (89.5+/-41.2 mL/min) than after water (121.5+/-54.7 mL/min).,Influence of grapefruit juice on cisapride pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[ml] / [min],89.5,268371,DB00604,Cisapride
,10223776,partial apparent metabolic clearance,Urinary norcisapride recovery was similar and thus the partial apparent metabolic clearance to norcisapride was lower (P = .046) after grapefruit juice (89.5+/-41.2 mL/min) than after water (121.5+/-54.7 mL/min).,Influence of grapefruit juice on cisapride pharmacokinetics. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223776/),[ml] / [min],121.5,268372,DB00604,Cisapride
,12621386,apparent inhibition constant (K(i)),"Although not a substrate for P-glycoprotein, cisapride inhibited P-glycoprotein with an apparent inhibition constant (K(i)) of 16.1 micromol/L.",Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621386/),[μM] / [l],16.1,272585,DB00604,Cisapride
